AHK-Cu
Copper tripeptide (Ala-His-Lys-Cu)
AHK-Cu (Copper tripeptide (Ala-His-Lys-Cu)) is a healing & recovery research compound. Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
AHK-Cu quick facts
| Reported research dose | 1mg-5mg |
| Route | Subq or topical |
| Frequency | 1x Daily |
| Half-life | Topical/local; short systemically |
| Forms | Injectable, Topical |
| Evidence level | In-vitro + topical |
The hair peptide — run alongside or instead of GHK-Cu for the scalp.
How AHK-Cu works
Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
Proposed benefits
Hair growth and scalp/skin support (copper peptide).
✅ Clinically validated
- No trials of injected AHK-Cu. Topical copper-peptide research is the relevant human evidence, and small controlled work on AHK-Cu specifically reported increased hair follicle size and stimulated dermal papilla cell proliferation.
📊 Correlative data
- Used topically and by injection for hair growth, usually alongside GHK-Cu. Reported experience is of a slower, subtler effect than minoxidil, and the same local reaction at injection sites that every copper peptide produces.
🧪 Theoretical / extrapolated
- A copper-binding tripeptide (Ala-His-Lys) closely related to GHK-Cu, with activity weighted toward hair follicle rather than general dermal repair — it upregulates VEGF in dermal papilla cells.
- Copper delivery is the mechanism and the ceiling, exactly as with GHK-Cu: copper is tightly regulated systemically, so more is not straightforwardly better and topical use has a far better rationale than injection.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
AHK-Cu — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- The copper is the active ingredient and also the constraint. Copper is an essential trace mineral with a genuine upper limit, and these deliver it directly.
- Topically over a small area this is not a systemic concern. Large surface areas, high concentrations, or injecting it are a different proposition — the same molecule at a different exposure.
What has actually been reported
- Topical use is well tolerated; irritation and temporary blue-green staining are the common complaints, both cosmetic.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Match the exposure to the goal. A face-sized area of a topical is a different proposition from full-body use or injection. Most of the cosmetic benefit is local, so there is rarely a reason to escalate to systemic exposure for a skin outcome.
- Keep it away from direct vitamin C in the same layer. Copper and ascorbic acid deactivate each other — this wastes both rather than harming you, but it is the most common way people get nothing from an expensive product. Vitamin C in the morning, copper at night.
- Don't stack multiple copper products at once. A copper serum, a copper shampoo and a copper body lotion are three doses of the same mineral, and the ceiling is on the mineral, not on the product.
- If you are injecting it or covering large areas long-term, serum copper and ceruloplasmin are the two markers that would actually show accumulation.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- If you are using this at scale or injecting it, serum copper and ceruloplasmin are the markers that would show accumulation.
Don't run this if
- Wilson's disease or any condition of copper handling — the mechanism is delivering the exact thing you cannot clear.
The honest unknown
- Cumulative copper load from long-term high-surface-area topical use has not been characterised.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get AHK-Cu
Buy AHK-Cu at Ion Peptide →AHK-Cu — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What AHK-Cu moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Copper, Serum — ↑ expected to rise
Only relevant at systemic doses — topical use does not meaningfully raise serum copper.
What to do: Not routinely needed. It matters if you are injecting it regularly or already have a copper-handling condition. - Ceruloplasmin — ◆ worth watching
The copper-carrying protein, and the one that tells you whether copper is bound and safe or free and reactive.
What to do: Read with serum copper, never alone. - Zinc, Plasma — ↓ expected to fall
Copper and zinc compete for absorption. Sustained copper loading predicts falling zinc, which then shows up as immune and taste changes that get blamed on something else.
What to do: If you are running copper systemically for months, check zinc.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for AHK-Cu — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for AHK-Cu — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside AHK-Cu
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anaemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 102 markers A–Z
AHK-Cu — frequently asked questions
What is AHK-Cu?
AHK-Cu (Copper tripeptide (Ala-His-Lys-Cu)) is a healing & recovery research compound. Copper-binding peptide focused on hair — promotes follicle growth and dermal microvascularization; the hair-oriented cousin of GHK-Cu.
Is the full AHK-Cu protocol on this page?
The reported research dose is on this page, along with how AHK-Cu works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of AHK-Cu?
AHK-Cu has an approximate half-life of Topical/local; short systemically, which is part of what determines how often it's dosed.
What forms does AHK-Cu come in?
AHK-Cu is available as: Injectable, Topical.
What's the evidence behind AHK-Cu?
Current evidence level: In-vitro + topical. AHK-Cu is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact AHK-Cu protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What AHK-Cu is used for
AHK-Cu appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.